Mar 30 2011
“This is a milestone for retigabine and our partnership with Valeant”
Meda's (STO:MEDAA) partner for retigabine, Valeant Pharmaceuticals International, Inc., today announced that the European Commission has granted the marketing authorization for Trobalt™ (retigabine) in the epilepsy therapy area.
"This is a milestone for retigabine and our partnership with Valeant", said Anders Lönner, CEO Meda AB.
Valeant has a collaboration agreement with the pharmaceutical company GlaxoSmithKline for the global commercialization of retigabine. Meda is entitled to receive royalties of between 6 - 8 percent on retigabine sales.